Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13D/A 0001493152-24-017664 0001689394 XXXXXXXX LIVE 1 Common Stock 01/05/2026 false 0000715446 03528H109 Anixa Biosciences, Inc. 3150 ALMADEN EXPRESSWAY SUITE 250 SAN JOSE CA 95118 Michael Catelani 408-708-9808 c/o Anixa Biosciences, Inc., 3150 Almaden Expressway, Suite 250 San Jose CA 95118 0001689394 N Michael Catelani PF N X1 2468103.00 0.00 2468103.00 0.00 2468103.00 N 7.0 IN Common Stock Anixa Biosciences, Inc. 3150 ALMADEN EXPRESSWAY SUITE 250 SAN JOSE CA 95118 7.0% 2,468,103 shares, consisting of: (i) 44,500 shares of common stock held directly and (ii) 2,423,603 shares of common stock issuable upon exercise of stock options held directly by Reporting Person and exercisable within 60 days. As of the date hereof, Mr. Catelani beneficially owns 2,468,103 shares of the Issuer, consisting of 44,500 shares of common stock held directly and 2,423,603 shares of common stock issuable upon exercise of stock options held directly and exercisable within 60 days. Such shares represent a total of 7.0% of the Issuer's outstanding shares of common stock, an increase from the 5.25% reported on Mr. Catelani's Schedule 13D. The change in ownership is the result of market purchases, the vesting of previously outstanding stock options and a change in the number of stock options that are not yet exercisable but will be exercisable within 60 days. The triggering event for this filing was the granting on January 5, 2026 of a stock option to Mr. Catelani to purchase up to 175,000 shares of common stock at a price of $3.18 per share. Mr. Catelani has the sole power to vote or direct the vote of, and to dispose or direct the disposition of, the entirety of the number of shares indicated immediately above. There are no other persons known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities. Michael Catelani /s/ Michael Catelani Michael Catelani 01/06/2026